CareDx (CDNA) Misses Q2 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
CareDx Reports Preliminary Second Quarter 2016 Financial Results
August 10, 2016 4:01 PM EDTBRISBANE, Calif., Aug. 10, 2016 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today reported preliminary financial results for the second quarter ended June 30, 2016.
Recent highlights:
Achieved total revenue for the second quarter of 2016 of $10.7 million AlloMap® revenues were $7.2 million in the quarterAlloMap patient results volumes in the U.S. were up by 12% year-over-yearOlerup® revenues contributed $3.4 million in the second quarter Advanced AlloSure®... More